

“Comparison of Marketing Strategies Between Branded Drug and Generic Drug”

Aman Yadav¹, Dr. Shashikant Maury^{2*}, Mr. Mohit Vishwakarma^{3*}, Prof. (Dr.) Mohd. Wasiullah^{4*}, Prof. (Dr.) Piyush Yadav^{5*}

1. Principal, Dept. of Pharmacy, Prasad Institute of Technology, Jaunpur (222001) U.P., India
 2. Academic Head, Dept. of Pharmacy, Prasad Institute of Technology, Jaunpur (222001) U.P., India
 3. Scholar, Dept. of Pharmacy, Prasad Institute of Technology, Jaunpur (222001) U.P., India
 4. Corresponding Author, Associate Professor, Dept. of Pharmacy, Prasad Institute of Technology, Jaunpur (222001) U.P., India
 5. Co-Author, Dept. of Pharmacy, Prasad Institute of Technology, Jaunpur (222001) U.P., India
- Corresponding Author Email Id:** skmaurya0008@gmail.com
-

Abstract:

In the pharmaceutical industry, comparing the marketing approaches of branded versus generic pharmaceuticals is a crucial field of research with consequences for patient access to treatment, healthcare policy, and market competition. Pharmacies that create and sell branded medications under patent protection frequently use intensive marketing initiatives to build brand awareness and increase market dominance. On the other hand, generic medications, which are bioequivalent to their branded equivalents but are usually marketed by several manufacturers following the expiration of their patent, present different marketing opportunities and obstacles.

With a focus on important components like promotional efforts, pricing tactics, distribution networks, and regulatory considerations, this study compares and analyzes the marketing methods used by makers of branded and generic drugs. By means of an extensive examination of extant literature, industry reports, and case studies, our aim is to clarify the distinctions in marketing strategies between these two pharmaceutical market segments and investigate the elements that impact their efficacy. The results of this study have consequences for consumers, pharmaceutical corporations, healthcare providers, and politicians. Through comprehension of the distinct marketing dynamics of branded and generic drugs, stakeholders can make informed decisions regarding drug prescribing, purchasing, and regulatory oversight.

Keywords: *Branded drugs, generic drugs, marketing strategies, pharmaceutical industry, healthcare policy etc.*

I. Introduction:

The pharmaceutical sector is distinguished by the division of pharmaceuticals into branded and generic products, each with unique marketing approaches designed to gain market share and satisfy patient demands. Pharmaceutical businesses that develop and market branded pharmaceuticals with patent protection use intensive marketing strategies to build brand awareness and set themselves apart from rivals. On the other hand, obtaining market acceptability and trust presents special difficulties for generic medications, which are bioequivalent to their branded equivalents but are usually marketed by several manufacturers following patent expiration.

The context for a comparison of the marketing approaches used for branded versus generic medications is established by this introduction. Policymakers, medical experts, pharmaceutical corporations, and consumers are among the stakeholders in the pharmaceutical sector who must comprehend the subtleties of these initiatives. Through an analysis of promotional initiatives, pricing tactics, distribution networks, and regulatory frameworks, we may acquire a deeper understanding of the elements influencing the triumph or downfall of marketing campaigns in both market sectors.

With this research, we hope to answer the following important questions: What are the main distinctions between the marketing approaches used by companies that make branded and generic drugs? What effects do these tactics have on patient access to medication, market competition, and healthcare costs? What legal requirements affect the way both generic and branded medications are marketed, and how do those requirements affect business practices? What can be gained from each segment's successful marketing strategies, and how can those lessons be used to advance pharmaceutical innovation and enhance patient outcomes.

II. Method:

A. Name Brand Substances:

I. Distinctive Branding: Brand medications make significant financial investments to develop distinctive brand identities through recognizable names, logos, and package styles. These components seek to set the product apart from rivals and build a strong visual relationship with it.

II. Direct-to-Consumer (DTC) Advertising: Brand medications frequently run direct marketing efforts that reach customers via print, digital, and television media. These advertisements seek to increase customer awareness and motivate people to ask their healthcare practitioners for the specific brand of medication.

III. Physician Marketing: Direct communication with healthcare professionals is facilitated by pharmaceutical sales representatives employed by brand medication makers. These delegates give doctors product information, samples, and educational materials in an effort to affect their prescribing choices and raise brand awareness among healthcare providers.

A. Medications Without Brand Names:

I. Labeling and Packaging: Although patent laws prevent generic medications from using brand names, they frequently employ labeling and packaging that is comparable to that of their name-brand equivalents. The objective of this technique is to improve identification and trust among customers and healthcare providers by utilizing the recognizable appearance of the brand drug.

II. Price and Value Proposition: Since generic medications are significantly less expensive than name-brand medications, price is the main area of competition for them. Marketing campaigns draw attention to this value offer by highlighting how accessible and inexpensive generic alternatives are.

III. Bioequivalence and Quality Assurance: Through labeling and advertising materials, generic medication producers highlight the bioequivalence and quality assurance of their medicines. Building confidence requires being transparent about regulatory clearance and adherence to safety and efficacy requirements.

Strategies for Marketing Communication:

A. Name Brand Medicine:

I. Differentiation: When marketing their unique selling propositions (USPs), brand medications often emphasize things like creative formulations, increased safety, efficacy, or convenience in comparison to generics. Highlight any unique features of the brand, such as patents, private technologies, or clinical research.

II. Recognition of Brands and Branding: Make an investment in developing a powerful brand identity by using visual components, brand storytelling, and consistent messaging. Make catchy taglines, logos, and brand names that appeal to your target market.

III. Content of Education: Create instructional resources aimed at consumers and healthcare professionals (HCPs) to build the brand's authority and reputation. Give comprehensive details regarding the drug's mode of action, clinical evidence, recommended dose, and any adverse effects.

B. Generic medication:

I. Messages to Cut Costs: Draw attention to the substantial cost reductions that generics provide as compared to their name-brand counterparts. Stress the accessibility and cost of generic medications, which increase access to healthcare for a larger number of people.

II. Comparability and Biosimilarity: Explain the regulatory approval procedure and provide evidence that the generic medication is safe, effective, and of comparable quality to its name-brand equivalent. Establish confidence between patients and healthcare professionals by utilizing FDA approvals and bioequivalency studies.

III. Education on Generic Substitution: Inform patients, healthcare providers, and the public about generic substitution and the laws and regulations that allow it. Dispel common myths regarding generic medications, such as those pertaining to their effectiveness or quality.

Channels of Distribution:

A. Name Brand Substances:

I. Pharmaceutical Wholesalers/Distributors: Pharmaceutical wholesalers or distributors are usually responsible for distributing brand-name medications to pharmacies, hospitals, clinics, and other healthcare facilities. These middlemen buy pharmaceuticals in bulk from producers and then transfer them to smaller pharmacies or medical facilities.

II. Direct Sales to Hospitals and Pharmacies: Pharmacies, hospitals, and other healthcare facilities may be the target of direct sales teams employed by pharmaceutical companies. These sales teams negotiate contracts and pricing arrangements while directly promoting the brand's products to these organizations' decision-makers.

III. Specialty Pharmacy Networks: Pharmaceutical companies frequently form partnerships with specialty pharmacy networks to supply specialist pharmaceuticals used to treat uncommon or complex illnesses. These pharmacies offer extra support services like patient education in addition to their specialty drug dispensing.

B. Medications that are generic:

I. Pharmaceutical wholesalers or distributors: Like brand medications, generic medications are supplied to pharmacies, hospitals, and other healthcare facilities by pharmaceutical wholesalers or distributors. These middlemen are essential to guaranteeing the prompt and effective release of generic drugs onto the market.

II. Generic Drug Repackagers: Before being supplied to pharmacies or medical facilities, generic medications occasionally undergo repackaging or relabeling by specialized repackaging businesses. Repackagers may provide services like personalized packaging or unit-dose dispensing in addition to guaranteeing adherence to legal standards.

III. Retail Pharmacies: Chain pharmacies, independent pharmacy, and supermarket pharmacies all carry a large selection of generic medications.

Strategies for Product Differentiation:

A. Name Brand Substances:

I. Novel Formulations: Brand medications frequently set themselves apart with novel formulations, such as extended-release pills, cutting-edge injectables or patches, or distinctive mixes of active components. By showcasing these developments, the brand can be positioned as innovative and superior in terms of convenience or effectiveness.

II. Patented substances or technology: A lot of name-brand medications include proprietary technology or patented substances that are only used in their formulations. By showcasing these patents and the scientific studies that supported them, the brand can be made to seem more credible and its high cost justified.

III. Clinical Evidence: To prove their safety, effectiveness, and superiority over current therapies, brand medications usually engage in lengthy clinical trials.

B. Medications Without Brand Names:

I. Economic Benefit: The main tactic used by generic medications to set themselves apart from name-brand alternatives is their lower cost. Stress the substantial cost reductions that generics provide to insurers, patients, and healthcare systems, which makes them a desirable choice for consumers and payers on a budget.

II. Compliance with Regulations and Bioequivalency: Make sure that generic medications adhere to the strict regulatory requirements and bioequivalency standards established by health authorities like the FDA. To inspire trust in patients and healthcare providers, explain to them how the generic medication is equivalent to the name-brand medication in terms of safety, effectiveness, and quality.

III. Conclusion:

To sum up, the pharmaceutical sector uses customized marketing techniques to successfully advertise both name-brand and generic medications. Brand medications, protected by patents, emphasize uniqueness, creativity, and direct brand awareness. Advertising. Conversely, generic medications prioritize cost-effectiveness, quality control, and regulatory compliance in their marketing campaigns since they are in direct competition with brand names in terms of price and accessibility once patents expire. Pharmaceutical businesses must comprehend these differences in order to successfully traverse the competitive landscape and cater to the various needs of customers and healthcare professionals.

Reference:

- [1]. Alfonso-Cristancho, R., Andia, T., Barbosa, T. and Watanabe, J.H. (2015), “Definition and classification of generic drugs across the world”, *Applied Health Economics and Health Policy*, Vol. 13, pp. 5-11.
- [2]. Anusha, K.S. (2016), “Brand a marketing mix: a review”, *Journal of Global Economics*, Vol. 4 No. 3, pp. 1-4. *Marketing Research*, Vol. 4 No. 3, pp. 291-295.
- [3]. Avery, R.J., Eisenberg, M.D. and Simon, K.I. (2012), “The impact of direct-to-consumer television and magazine advertising on antidepressant use”, *Journal of Health Economics*, Vol. 31 No. 5, pp. 705-718.

- [4]. Benci, L. (2007), *La Prescrizione e la Somministrazione Dei Farmaci*, McGraw Hill, Milano. Berndt, E.R., Mortimer, R., Bhattacharjya, A., Parece, A. and Tuttle, E. (2007), “Authorized generic drugs, price competition, and consumers’ welfare”, *Health Affairs*, Vol. 26 No. 3, pp. 790-799.
- [5]. Biga, J., Taboulet, F., Lapeyre-Mestre, M., Duguet, A.M., Vincent, S. and Montastruc, J.L. (2005), “Prescribing drugs by international non-proprietary name: the perception of health and non-health professionals”, *Therapies*, Vol. 60 No. 4, pp.401-407.
- [6]. Bobbio, M. (2001), “Le nuove ‘Note’ limitative della Commissione Unica del Farmaco”, *Italian Health Journal*, Vol. 2 No. 1, pp. 35-40. Bottenberg, R.A. and Ward, J.H. (1963), *Applied Multiple Linear Regression*, 6570th Personnel Research Laboratory, Aerospace Medical Division, Air Force Systems Command, Lackland Air Force Base, Vol. 63 No. 6 of *Health Economics, V Economics*, Vol. Chiplunkar, S., Gowda, D. and Shivakumar, H. (2020), “*Allied Sciences*, Vol. 9 No. 5, pp. 11-11.
- [7]. Danciu, V. (2014), “Manipulative marketing: persuasion and manipulation of the consumer through advertising”, *Theoretical and Applied Economics*, Vol. 21 No. 2, pp. 591-601. *European Journal of Clinical Pharmacology*
- [8]. Dickov, V. and Kuzman, B. (2011), “Specific features of pharmaceuticals marketing mix”, *Journal of Management and Marketing in Healthcare*, Vol. 4 No. 3, pp. 160-167. Dodds, W.B., Monroe, K.B. and Grewal, D. (1991), “Effects of price, brand, and store information on buyers’ product evaluations”, *Journal of Marketing Research*, Vol. 28 No. 3, pp. 307-319.
- [9]. Dupuits, F.M. (2002), “The effects of the internet on pharmaceutical consumers and providers”, *Disease Management and Health Outcomes*, Vol. 10 No. 11, pp. 679-691.